Market Overview:
The global CDK 4 and 6 inhibitor drug market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for targeted therapies, and growing focus on personalized medicine. In addition, the increasing number of clinical trials for CDK 4 and 6 inhibitors is also contributing to the growth of this market. The global CDK 4 and 6 inhibitor drug market can be segmented on the basis of type into injection, oral, and other types. The injection segment is expected to dominate this market during the forecast period owing to its high efficacy as compared to other types of drugs. On the basis of application, hospitals are expected to account for a major share in this market due their large patient population base suffering from various forms of cancer.
Product Definition:
CDK 4 and 6 inhibitors are a type of cancer drug that blocks the activity of enzymes called cyclin-dependent kinases 4 and 6 (CDK4/6). These drugs help to stop the growth of cancer cells.
Injection:
Injection is a medication used to treat diseases caused by abnormal cell growth. The most common use of the injection is in the treatment of cancer, which involves uncontrolled and abnormal cell growth. In addition, it also has applications in other fields such as gynecology and immunology. The drug works by blocking an enzyme called cyclin-dependent kinase 4 (CDK 4) or cyclin-dependent kinase 6 (CDK 6).
Oral:
Oral is a drug that prevents the breakdown of cyclic adenosine monophosphate (cAMP) in target tissues. It has several uses in cancer treatment such as to treat bladder cancer, creams used for pain relief after surgery, and preventing nausea and vomiting during chemotherapy. Inhibitors oral are used to treat diseases caused by mutations in CDK 4 & 6 gene which includes lysosomal storage disorders such as Gaucher disease and Fabry disease among others.
Application Insights:
The other application segment includes research settings and home care settings. In the research setting, these drugs are used for various purposes including the study of cancer biology, oncology drug development and testing. They are also used in preclinical trials to test the safety and efficacy of new molecules for treating cancerous tumors. The use of these inhibitors in clinical trials is increasing due to their ability to block CDK 4/6 kinases which has led to an increase in overall survival rates among patients suffering from advanced cancers such as lung, breast or colorectal cancer.
In addition, they have a high potential as a second-line therapy owing to improved patient compliance with treatment along with fewer side effects when compared with first-line therapies such as chemotherapy or radiotherapy that employ similar mechanisms of action thus making them highly suitable for this purpose throughout 2018 - 2030 ¢â‚¬â€œ 28%.
Regional Analysis:
North America dominated the global CDK 4 and 6 inhibitor drug market in 2017. The presence of key players, favorable government initiatives, rising prevalence of cancer and other diseases such as cardiovascular diseases (CVDs), type 2 diabetes (T2D), obesity, & arthritis are some major factors contributing to the growth of this region. For instance, in November 2016; FDA approved Novartis AG & Co’s proposal for an accelerated approval for GDC-0941 that is a once weekly injection for treatment of relapsed or refractory chronic lymphocytic leukemia.
Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to increasing R&D activities by various pharmaceutical companies coupled with growing healthcare expenditure in emerging countries such as China and India.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for CDK 4 and 6 inhibitors market. According to the American Cancer Society, approximately 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and about 600,920 people will die from the disease. This number is expected to rise significantly in upcoming years due to growing population and aging population.
- Rising demand for targeted therapies: The rising demand for targeted therapies is another key growth driver for CDK 4 and 6 inhibitors market as these drugs offer better treatment outcomes with fewer side effects as compared to traditional chemotherapy regimens. For instance, Pfizer’s palbociclib (Ibrance) was approved by FDA in 2015 for treatment of estrogen receptor-positive (ER+) advanced breast cancer patients who have received prior therapy including an aromatase inhibitor or tamoxifen citrate (Nolvadex).
- Technological advancements: Technological advancements are also propelling the growth of CDK 4 and 6 inhibitors market as they are enabling development of novel drugs with improved efficacy and safety profiles. For instance, Novartis’ Kisqali (ribociclib), a CDK4/6 inhibitor approved by FDA in March 2017 for treatment of postmenopausal women with hormone receptor-positive (HR+) advanced or metastatic breast cancer was developed using company’s proprietary kinase inhibition platform called
Scope Of The Report
Report Attributes
Report Details
Report Title
CDK 4 and 6 Inhibitor Drug Market Research Report
By Type
Injection, Oral, Other
By Application
Hospitals, Clinics, Retail Pharmacies, Other
By Companies
Pfizer, Novartis, Eli Lilly
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global CDK 4 and 6 Inhibitor Drug Market Report Segments:
The global CDK 4 and 6 Inhibitor Drug market is segmented on the basis of:
Types
Injection, Oral, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Retail Pharmacies, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- Eli Lilly
Highlights of The CDK 4 and 6 Inhibitor Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Injection
- Oral
- Other
- By Application:
- Hospitals
- Clinics
- Retail Pharmacies
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the CDK 4 and 6 Inhibitor Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
CDK 4 inhibitors are drugs that block the activity of CDK4. This can slow down the growth of cancer cells. CDK 6 inhibitors work in a similar way, by blocking the activity of CDK6.
Some of the key players operating in the cdk 4 and 6 inhibitor drug market are Pfizer, Novartis, Eli Lilly.
The cdk 4 and 6 inhibitor drug market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 CDK 4 and 6 Inhibitor Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 CDK 4 and 6 Inhibitor Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 CDK 4 and 6 Inhibitor Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the CDK 4 and 6 Inhibitor Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global CDK 4 and 6 Inhibitor Drug Market Size & Forecast, 2020-2028
4.5.1 CDK 4 and 6 Inhibitor Drug Market Size and Y-o-Y Growth
4.5.2 CDK 4 and 6 Inhibitor Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Injection
5.2.2 Oral
5.2.3 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Retail Pharmacies
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global CDK 4 and 6 Inhibitor Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 CDK 4 and 6 Inhibitor Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Injection
9.6.2 Oral
9.6.3 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Retail Pharmacies
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Injection
10.6.2 Oral
10.6.3 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Retail Pharmacies
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Injection
11.6.2 Oral
11.6.3 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Retail Pharmacies
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Injection
12.6.2 Oral
12.6.3 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Retail Pharmacies
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Injection
13.6.2 Oral
13.6.3 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Retail Pharmacies
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 CDK 4 and 6 Inhibitor Drug Market: Competitive Dashboard
14.2 Global CDK 4 and 6 Inhibitor Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Novartis
14.3.3 Eli Lilly
